구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Remicade® |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Ankylosing Spondylitis |
Overview Indication | Crohn's Disease |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel alternative targets with improved efficacy and safety profiles to treat RA |
MoA Mechanism | targeted metabolomics, to delineate microbial and metabolic signatures predictive of IFX induction efficacy and to explore mechanistic pathway |
MoA Biomarker | biomarkers and safety profile were noted before and after switch |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Safety signal | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Result source | ClinicalTrials.gov NCT02990806 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02990806 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Remicade® |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Ankylosing Spondylitis |
Overview Indication | Crohn's Disease |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel alternative targets with improved efficacy and safety profiles to treat RA |
MoA Mechanism | targeted metabolomics, to delineate microbial and metabolic signatures predictive of IFX induction efficacy and to explore mechanistic pathway |
MoA Biomarker | biomarkers and safety profile were noted before and after switch |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Safety signal | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Result source | ClinicalTrials.gov NCT02990806 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02990806 |
추천 비교
추천 비교